

# CITATION REPORT

List of articles citing

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro

DOI: 10.1046/j.1365-2680.2001.00231.x

Autonomic and Autacoid Pharmacology, 2001, 21, 243-8.

**Source:** <https://exaly.com/paper-pdf/32979470/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
139	Muscarinic receptor subtypes and management of the overactive bladder. <b>2002</b> , 60, 82-8; discussion 88-9		105
138	Muscarinic receptors: what we know. <b>2003</b> , 4, 421-8		32
137	[New pharmacological treatment concepts for overactive bladder]. <i>Der Urologe</i> , <b>2003</b> , 42, 807-11		0
136	Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2003</b> , 367, 524-31	3.4	52
135	Antimuscarinics and the overactive detrusor--which is the main mechanism of action?. <b>2003</b> , 43, 1-5		229
134	Advances in medical management of overactive bladder. <b>2003</b> , 78, 681-3		6
133	Signal transduction underlying carbachol-induced contraction of human urinary bladder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2004</b> , 309, 1148-53	4.7	142
132	Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca <sup>2+</sup> sources. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2004</b> , 308, 47-53	4.7	71
131	Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. <b>2004</b> , 5, 2351-9		11
130	Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2004</b> , 310, 1255-65	4.7	54
129	The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. <b>2004</b> , 286, R874-80		82
128	Role of serotonin and noradrenaline in stress urinary incontinence. <b>2004</b> , 94 Suppl 1, 23-30		28
127	Antimuscarinics for treatment of overactive bladder. <b>2004</b> , 3, 46-53		334
126	Muscarinic receptors mediating contraction of female mouse urinary bladder: effects of oestrogen. <b>2004</b> , 487, 205-11		5
125	Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overactive bladder. <b>2004</b> , 8, 17-22		5
124	An appraisal of recently patented compounds for bladder overactivity and urinary incontinence. <b>2004</b> , 14, 1041-1060		3
123	Potential therapeutic targets for the treatment of detrusor overactivity. <b>2004</b> , 8, 95-106		21

122	Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. <b>2004</b> , 13, 1493-500		28
121	Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. <b>2005</b> , 45, 961-8		6
120	QT and QTc interval with standard and suprathreshold doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. <b>2005</b> , 45, 1038-47		47
119	Neuronal nitric oxide synthase activity in rat urinary bladder detrusor: participation in M3 and M4 muscarinic receptor function. <b>2005</b> , 25, 93-100		5
118	Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. <b>2005</b> , 53, 2195-201		170
117	An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. <b>2005</b> , 95, 580-6		83
116	Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. <b>2005</b> , 144, 1089-99		171
115	Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. <b>2005</b> , 145, 608-19		38
114	Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. <b>2005</b> , 48, 471-7		65
113	Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. <b>2005</b> , 23, 248-52		72
112	Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. <b>2005</b> , 44, 1021-5		59
111	Therapy Insight: bladder dysfunction associated with multiple sclerosis. <b>2005</b> , 2, 492-501		52
110	The Neuro-Urological Connection. <b>2005</b> , 4, 18-28		20
109	Cholinergic and purinergic responses in isolated human detrusor in relation to age. <i>Journal of Urology</i> , <b>2005</b> , 173, 2182-9	2.5	33
108	Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. <i>Journal of Urology</i> , <b>2005</b> , 174, 1743-8	2.5	43
107	Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. <b>2005</b> , 65, 238-42		87
106	The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. <b>2006</b> , 7, 509-27		6
105	Local effects of antimuscarinics. <b>2006</b> , 33, 511-8, ix-x		12

104	Darifenacin: Pharmacology and clinical usage. <b>2006</b> , 33, 475-82, viii		11
103	The clinical pharmacokinetics of darifenacin. <b>2006</b> , 45, 325-50		48
102	Transdermal drug delivery treatment for overactive bladder. <b>2006</b> , 32, 513-20		13
101	Oxybutynin and its new transdermal application for the treatment of overactive bladder. <b>2006</b> , 2, 225-30		
100	Developments in pharmacological therapy for the overactive bladder. <b>2006</b> , 98 Suppl 1, 78-87; discussion 88-9		6
99	Muscarinic receptors in the bladder: from basic research to therapeutics. <b>2006</b> , 147 Suppl 2, S80-7		169
98	Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. <b>2006</b> , 148, 565-78		399
97	Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. <b>2006</b> , 17, 239-47		49
96	Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2006</b> , 374, 87-97	3-4	34
95	Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. <b>2006</b> , 50, 317-26		192
94	Muscarinic regulation of neonatal rat bladder spontaneous contractions. <b>2006</b> , 291, R1049-59		27
93	Aging impairs neurogenic contraction in guinea pig urinary bladder: role of oxidative stress and melatonin. <b>2007</b> , 293, R793-803		25
92	Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. <b>2007</b> , 30, 2324-7		6
91	Darifenacin for the treatment of overactive bladder. <b>2007</b> , 3, 143-147		
90	Developments in the pharmacotherapy of the overactive bladder. <b>2007</b> , 17, 223-30		13
89	Darifenacin treatment of patients $\geq$ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. <b>2007</b> , 23, 2347-58		75
88	Urge Urinary Incontinence. <b>2007</b> ,		
87	M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors. <i>Neurourology and Urodynamics</i> , <b>2007</b> , 26, 63-70	2.3	26

86	Molecular characterization of M2 and M3 muscarinic receptor expression in bladder from women with refractory idiopathic detrusor overactivity. <b>2007</b> , 99, 1433-8	26
85	The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. <b>2007</b> , 100, 574-8	22
84	Evolution of transdermal oxybutynin in the treatment of overactive bladder. <b>2008</b> , 62, 167-70	13
83	"Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. <b>2007</b> , 73, 737-51	58
82	Contribution of Ca <sup>2+</sup> influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. <b>2007</b> , 565, 180-9	36
81	Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. <b>2007</b> , 52, 531-8	46
80	Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. <b>2007</b> , 52, 848-9	1
79	[Treatment of overactive bladder in elderly and old people]. <i>Der Urologe</i> , <b>2007</b> , 46, 382-6	1
78	Muscarinic receptors: What we know. <b>2007</b> , 2, 29-36	
77	Propriétés pharmacologiques de l'oxybutynine sur la fonction vésicale chez la souris. <b>2007</b> , 2, 12-19	
76	Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2008</b> , 456, 349-58	4.6 8
75	Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. <b>2008</b> , 62, 1792-800	112
74	Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. <b>2008</b> , 101, 371-5	65
73	Tolterodine does not affect memory assessed by passive-avoidance response test in mice. <b>2008</b> , 579, 225-8	7
72	Structure and dynamics of the full-length M1 muscarinic acetylcholine receptor studied by molecular dynamics simulations. <b>2008</b> , 469, 142-50	10
71	Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. <b>2008</b> , 13, 241-51	53
70	Role of fesoterodine in the treatment of overactive bladder. <b>2009</b> , 2, 1-9	2
69	Urinary urgency - translating the evidence base into daily clinical practice. <b>2009</b> , 63, 1675-82	7

68	In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. <b>2009</b> , 156, 807-17		13
67	Pharmacologic responses of the mouse urinary bladder. <b>2009</b> , 4, 192-197		3
66	AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. <b>2010</b> , 160, 1119-27		7
65	New once-daily formulation for trospium in overactive bladder. <b>2010</b> , 64, 1535-1540		9
64	Muscarinic Receptor Antagonists, the Overactive Bladder and Efficacy against Urinary Urgency. <b>2010</b> , 2, CMT.S4606		3
63	Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol. <b>2011</b> , 78, 1442.e9-15		38
62	Pharmacodynamics of Overactive Bladder Drugs: Shifting the Curve. <b>2011</b> , 6, 51-63		4
61	Efficacy and tolerability of solifenacin in patients aged $\geq 65$ years with overactive bladder: post-hoc analysis of 2 open-label studies. <b>2011</b> , 123, 94-104		11
60	Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2011</b> , 338, 220-7	4-7	9
59	Sickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia. <b>2012</b> , 2012, 723520		9
58	Non-adrenergic, non-cholinergic, non-purinergeric contractions of the urothelium/lamina propria of the pig bladder. <b>2012</b> , 32, 53-9		14
57	Muscarinic agonists and antagonists: effects on the urinary bladder. <b>2012</b> , 375-400		32
56	[Medical therapy of lower urinary tract symptoms [corrected]]. <i>Der Urologe</i> , <b>2012</b> , 51, 1125-36		0
55	Muscarinic receptor subtypes involved in urothelium-derived relaxatory effects in the inflamed rat urinary bladder. <i>Autonomic Neuroscience: Basic and Clinical</i> , <b>2012</b> , 170, 5-11	2-4	12
54	Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. <b>2012</b> , 29, 259-73		61
53	Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia. <b>2013</b> , 8, 1013-27		10
52	[New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder]. <b>2013</b> , 37, 83-91		3
51	New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder. <b>2013</b> , 37, 83-91		5

50	Differential effects of selective and non-selective muscarinic antagonists on gastrointestinal transit and bowel function in healthy women. <b>2013</b> , 25, e35-43		5
49	Activation of muscarinic M3 receptors inhibits large-conductance voltage- and Ca <sup>2+</sup> -activated K <sup>+</sup> channels in rat urinary bladder smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , <b>2013</b> , 305, C207-14	5.4	14
48	Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. <b>2013</b> , 54, 806-15		30
47	New therapies in the treatment of overactive bladder. <b>2013</b> , 18, 319-37		8
46	Non-neuronal functions of the m2 muscarinic acetylcholine receptor. <b>2013</b> , 4, 171-97		15
45	Gene expression of muscarinic, tachykinin, and purinergic receptors in porcine bladder: comparison with cultured cells. <b>2013</b> , 4, 148		7
44	Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro. <b>2014</b> , 35, 74-81		7
43	Pharmacological treatment of urinary incontinence. <b>2014</b> , 20, 185-202		4
42	Regulation of ACh release from guinea pig bladder urothelial cells: potential role in bladder filling sensations. <b>2014</b> , 171, 3394-403		25
41	Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. <b>2014</b> , 23, 1365-74		8
40	Interstitial cells: regulators of smooth muscle function. <b>2014</b> , 94, 859-907		278
39	Design, synthesis, and evaluation of dihydropyrimidinone (DHPM) based muscarinic receptor antagonist. <i>Medicinal Chemistry Research</i> , <b>2015</b> , 24, 1763-1775	2.2	8
38	Activation of P2Y6 Receptors Facilitates Nonneuronal Adenosine Triphosphate and Acetylcholine Release from Urothelium with the Lamina Propria of Men with Bladder Outlet Obstruction. <i>Journal of Urology</i> , <b>2015</b> , 194, 1146-54	2.5	24
37	Novel mechanism of hydrogen sulfide-induced guinea pig urinary bladder smooth muscle contraction: role of BK channels and cholinergic neurotransmission. <i>American Journal of Physiology - Cell Physiology</i> , <b>2015</b> , 309, C107-16	5.4	19
36	Functional link between muscarinic receptors and large-conductance Ca <sup>2+</sup> -activated K <sup>+</sup> channels in freshly isolated human detrusor smooth muscle cells. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2015</b> , 467, 665-75	4.6	10
35	Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	2
34	Big-conductance Ca-activated K channels in physiological and pathophysiological urinary bladder smooth muscle cells. <i>Channels</i> , <b>2016</b> , 10, 355-364	3	5
33	Contractile effects and receptor analysis of adenosine-receptors in human detrusor muscle from stable and neuropathic bladders. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2016</b> , 389, 921-9	3.4	15

32	[The ice water test and bladder cooling reflex. Physiology, pathophysiology and clinical importance]. <i>Der Urologe</i> , <b>2016</b> , 55, 499-505		2
31	The importance of muscarinic receptors in domestic animal diseases and therapy: Current and future perspectives. <i>Veterinary Journal</i> , <b>2016</b> , 208, 13-21	2.5	4
30	Autonomic Receptor-mediated Regulation of Production and Release of Nitric Oxide in Normal and Malignant Human Urothelial Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 257-265	3.1	3
29	Benign prostatic hyperplasia [medicamentous treatment. <i>Medicina</i> , <b>2017</b> , 53, 273-284		
28	BPO/LUTS [Aktuelles zur medikamentösen Therapie. <i>Journal Fur Urologie Und Urogynakologie</i> , <b>2019</b> , 26, 114-120	0	
27	Design and synthesis of muscarinic acetylcholine receptor (mAChR) antagonist: pharmacophore-based screening and structure-based optimization. <i>Monatshefte Für Chemie</i> , <b>2019</b> , 150, 1335-1347	1.4	1
26	Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel. <i>Spinal Cord</i> , <b>2019</b> , 57, 662-668	2.7	2
25	Functional atropine sensitive purinergic responses in the healthy rat bladder. <i>Autonomic Neuroscience: Basic and Clinical</i> , <b>2020</b> , 227, 102693	2.4	1
24	Dysfunctional bladder neurophysiology in urofacial syndrome Hpse2 mutant mice. <i>Neurourology and Urodynamics</i> , <b>2020</b> , 39, 1930-1938	2.3	2
23	Bladder Outlet Obstruction and Overactive Bladder in Males. <i>Urodynamics, Neurourology and Pelvic Floor Dysfunctions</i> , <b>2021</b> , 67-85	0.1	
22	Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. <i>The Cochrane Library</i> , <b>2021</b> , 2, CD012336	5.2	1
21	Potential of Muscarinic M Receptor Activation through a New Allosteric Site with a Novel Positive Allosteric Modulator ASP8302. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2021</b> , 379, 64-73	4.7	0
20	Quantitative Analysis of the Levels of Expression of Muscarinic Receptor Subtype RNA in the Detrusor Muscle of Patients with Overactive Bladder. <b>2004</b> , 8, 17		4
19	Geriatric population. <b>2007</b> , 385-393		1
18	Medical management of neurogenic bladder with oral therapy. <i>Translational Andrology and Urology</i> , <b>2016</b> , 5, 51-62	2.3	26
17	Solifenacin-induced acute psychosis: a case report. <i>Annals of General Psychiatry</i> , <b>2021</b> , 34, e100586	5.3	0
16	Neurophysiological Control of Bladder Function. <b>2007</b> , 19-33		
15	Neurophysiology of Micturition: What's New?. <b>2009</b> , 17-33		



14 Antimuscarinic Treatments in Overactive Bladder. 170-177

13 A  $\beta$  Agonist, Mirabegron for the Treatment of Overactive Bladder. *UroToday International Journal*, **2011**, 04,

12 The Bladder as a Dynamic System. **2013**, 1-23

11 Lower Urinary Tract Symptoms and Benign Prostate Diseases in Older Men. **2014**, 251-271

10 Relevant Anatomy, Physiology, and Pharmacology. *Current Clinical Urology*, **2014**, 3-18

9 Benign Prostat Hiperplazisi ve Antimuskarinik Tedavi. *Anadolu Kliniği Tıp Bilimleri Dergisi*, **2016**, 21, 163-168.3

8 Risk Prediction Method for Anticholinergic Action Using Auto-quantitative Structure-Activity Relationship and Docking Study with Molecular Operating Environment. *Chemical and Pharmaceutical Bulletin*, **2020**, 68, 773-778 1.9

7 Management of overactive bladder with transdermal oxybutynin. *Reviews in Urology*, **2006**, 8, 93-103 1 9

6 Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. *Missouri Medicine*, **2016**, 113, 207-14 0.8 14

5 Neurophysiology of Micturition: What's New?. **2009**, 17-33

4 Moxibustion attenuates neurogenic detrusor overactivity in spinal cord injury rats by inhibiting M2/ATP/P2X3 pathway.. *Brain Research*, **2022**, 147926 3.7 0

3 Neurogenic defects underlie functional bladder outflow tract obstruction associated with biallelic variants inLRIG2. 0

2 Mechanism of traditional Chinese medicine in treating overactive bladder. 0

1 Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options. **2023**, 40, 241-261 0